Puriblood Medical Co., Ltd. (TPEX:6847)

Taiwan · Delayed Price · Currency is TWD

71.10

+0.20 (0.28%)

Nov 6, 2026, 1:22 PM CST

Market Cap	1.01B -5.7%
Revenue (ttm)	80.54M -31.4%
Net Income	-55.81M
EPS	-3.92
Shares Out	14.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,410
Open	67.90
Previous Close	70.90
Day's Range	64.50 - 71.10
52-Week Range	47.75 - 93.70
Beta	0.14
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Puriblood Medical

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan. [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2015

Employees 38

Stock Exchange Taipei Exchange

Ticker Symbol 6847

Full Company Profile

Financial Performance

In 2025, Puriblood Medical's revenue was 82.34 million, a decrease of -25.61% compared to the previous year's 110.67 million. Losses were -39.00 million, 626.7% more than in 2024.

Financial Statements